产品
编 号：F293119
分子式：C46H83N13O11
分子量：994.23
分子式：C46H83N13O11
分子量：994.23
产品类型
规格
价格
是否有货
结构图
CAS No: 251579-55-2
产品详情
生物活性：
ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD).
体内研究：
ABT-510 (100 mg/kg；腹腔注射；每天一次，持续90天) 在体内诱导细胞凋亡，使小鼠的卵巢上皮肿瘤大小、腹水量和继发性病变扩散显著减少。ABT-510 (60 mg/kg；皮下渗透微型泵；每天一次，持续7天) 降低炎症性肠病小鼠模型中的血管生成和炎症。Animal Model:TSP-1-Null mice (C57BL/6 background; orthotopic, syngeneic model of epithelial ovarian cancer).
Dosage:100 mg/kg
Administration:Intraperitoneal injection; single daily for 90 days
Result:Reduced ovarian tumor growth in wild-type and TSP-1-Null Mice.Significantly reduced the volume of ascites and completely abolished the formation of peritoneal lesions.Reversed ovarian tumor hypervascularization and increased the proportion of mature blood vessels.
Animal Model:TSP-1-Null mice (C57BL/6 background; 6-week-old; DSS-induced inflammatory bowel disease murine model).
Dosage:60 mg/kg
Administration:Subcutaneously implanted osmotic minipumps (0.5μL/h); single daily for 7 days
Result:Significantly delayed DSS-induced bleeding and improved the overall severity of disease.Significantly diminished inflammation grading and angiogenesis
体外研究：
ABT-510 (1，5，10，20，50 nM；24 h) 诱导 ID 8 细胞凋亡，(50 nM，24 h) 增加人类上皮性癌症细胞系 SKOV3、OVCAR3 和 CAOV3 的凋亡发生率。ABT-510 (0-10 μM; 7 天) 抑制了 NO 刺激的血管细胞向细胞外基质的生长和侵袭。ABT-510 可阻断肿瘤驱动的血管细胞生长、NO 驱动的 cGMP 通量以及 CD36 介导的脂肪酸吸收。。
ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD).
体内研究：
ABT-510 (100 mg/kg；腹腔注射；每天一次，持续90天) 在体内诱导细胞凋亡，使小鼠的卵巢上皮肿瘤大小、腹水量和继发性病变扩散显著减少。ABT-510 (60 mg/kg；皮下渗透微型泵；每天一次，持续7天) 降低炎症性肠病小鼠模型中的血管生成和炎症。Animal Model:TSP-1-Null mice (C57BL/6 background; orthotopic, syngeneic model of epithelial ovarian cancer).
Dosage:100 mg/kg
Administration:Intraperitoneal injection; single daily for 90 days
Result:Reduced ovarian tumor growth in wild-type and TSP-1-Null Mice.Significantly reduced the volume of ascites and completely abolished the formation of peritoneal lesions.Reversed ovarian tumor hypervascularization and increased the proportion of mature blood vessels.
Animal Model:TSP-1-Null mice (C57BL/6 background; 6-week-old; DSS-induced inflammatory bowel disease murine model).
Dosage:60 mg/kg
Administration:Subcutaneously implanted osmotic minipumps (0.5μL/h); single daily for 7 days
Result:Significantly delayed DSS-induced bleeding and improved the overall severity of disease.Significantly diminished inflammation grading and angiogenesis
体外研究：
ABT-510 (1，5，10，20，50 nM；24 h) 诱导 ID 8 细胞凋亡，(50 nM，24 h) 增加人类上皮性癌症细胞系 SKOV3、OVCAR3 和 CAOV3 的凋亡发生率。ABT-510 (0-10 μM; 7 天) 抑制了 NO 刺激的血管细胞向细胞外基质的生长和侵袭。ABT-510 可阻断肿瘤驱动的血管细胞生长、NO 驱动的 cGMP 通量以及 CD36 介导的脂肪酸吸收。。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备